These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 10191415)

  • 1. CCR5 genotype and human immunodeficiency virus (HIV)-specific mucosal antibody in seronegative women at high risk for HIV infection.
    Williams SB; Flanigan TP; Artenstein AW; VanCott TC; Smith D; Mayer K; Koup RA
    J Infect Dis; 1999 May; 179(5):1310-2. PubMed ID: 10191415
    [No Abstract]   [Full Text] [Related]  

  • 2. Natural mucosal antibodies reactive with first extracellular loop of CCR5 inhibit HIV-1 transport across human epithelial cells.
    Bomsel M; Pastori C; Tudor D; Alberti C; Garcia S; Ferrari D; Lazzarin A; Lopalco L
    AIDS; 2007 Jan; 21(1):13-22. PubMed ID: 17148963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human immunodeficiency virus (HIV)-specific cytotoxic T lymphocyte activity in HIV-exposed seronegative persons.
    Bernard NF; Yannakis CM; Lee JS; Tsoukas CM
    J Infect Dis; 1999 Mar; 179(3):538-47. PubMed ID: 9952359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human immunodeficiency virus (HIV)-specific IgA and HIV neutralizing activity in the serum of exposed seronegative partners of HIV-seropositive persons.
    Mazzoli S; Lopalco L; Salvi A; Trabattoni D; Lo Caputo S; Semplici F; Biasin M; Bl C; Cosma A; Pastori C; Meacci F; Mazzotta F; Villa ML; Siccardi AG; Clerici M
    J Infect Dis; 1999 Sep; 180(3):871-5. PubMed ID: 10438383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effects of CCR5-delta32, CCR2-64I and SDF-1-3'A polymorphic alleles on human immunodeficiency virus 1 (HIV-1) infection in the Polish population].
    Wasik TJ; Smoleń J; Kruszyński P; Bratosiewicz-Wasik J; Beniowski M
    Wiad Lek; 2005; 58(9-10):500-7. PubMed ID: 16529059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mucosal and systemic immune activation is present in human immunodeficiency virus-exposed seronegative women.
    Biasin M; Caputo SL; Speciale L; Colombo F; Racioppi L; Zagliani A; Blé C; Vichi F; Cianferoni L; Masci AM; Villa ML; Ferrante P; Mazzotta F; Clerici M
    J Infect Dis; 2000 Nov; 182(5):1365-74. PubMed ID: 11023460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of genetic polymorphisms in CCR5, CCR2, stromal cell-derived factor-1, RANTES, and dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin in seronegative individuals repeatedly exposed to HIV-1.
    Liu H; Hwangbo Y; Holte S; Lee J; Wang C; Kaupp N; Zhu H; Celum C; Corey L; McElrath MJ; Zhu T
    J Infect Dis; 2004 Sep; 190(6):1055-8. PubMed ID: 15319853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Frequency of CCR5-Delta32 deletion in human immunodeficiency virus type 1 (HIV-1) in healthy blood donors, HIV-1-exposed seronegative and HIV-1-seropositive individuals of southern Brazilian population.
    Reiche EM; Ehara Watanabe MA; Bonametti AM; Morimoto HK; Akira Morimoto A; Wiechmann SL; Matsuo T; Carvalho De Oliveira J; Vissoci Reiche F
    Int J Mol Med; 2008 Nov; 22(5):669-75. PubMed ID: 18949389
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Limited protective effect of the CCR5Delta32/CCR5Delta32 genotype on human immunodeficiency virus infection incidence in a cohort of patients with hemophilia and selection for genotypic X4 virus.
    Iversen AK; Christiansen CB; Attermann J; Eugen-Olsen J; Schulman S; Berntorp E; Ingerslev J; Fugger L; Scheibel E; Tengborn L; Gerstoft J; Dickmeiss E; Svejgaard A; Skinhøj P
    J Infect Dis; 2003 Jan; 187(2):215-25. PubMed ID: 12552446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemokine receptor polymorphisms and human immunodeficiency virus disease progression.
    Easterbrook PJ; Rostron T; Ives N; Troop M; Gazzard BG; Rowland-Jones SL
    J Infect Dis; 1999 Oct; 180(4):1096-105. PubMed ID: 10479136
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human immunodeficiency virus type 1 disease progression, CCR5 genotype, and specific immune responses.
    Visco-Comandini U; Hultgren C; Broström C; Birk M; Kim S; Sällberg M
    Clin Diagn Lab Immunol; 1998 Jul; 5(4):463-6. PubMed ID: 9665949
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Viral evolution in macaques coinfected with CCR5- and CXCR4-tropic SHIVs in the presence or absence of vaccine-elicited anti-CCR5 SHIV neutralizing antibodies.
    Burke B; Derby NR; Kraft Z; Saunders CJ; Dai C; Llewellyn N; Zharkikh I; Vojtech L; Zhu T; Srivastava IK; Barnett SW; Stamatatos L
    Virology; 2006 Nov; 355(2):138-51. PubMed ID: 16920175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CC chemokine receptor 5 cell-surface expression in relation to CC chemokine receptor 5 genotype and the clinical course of HIV-1 infection.
    de Roda Husman AM; Blaak H; Brouwer M; Schuitemaker H
    J Immunol; 1999 Oct; 163(8):4597-603. PubMed ID: 10510404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemokine receptors CCR5 and CCR2 genes in HIV positive, HIV exposed seronegative and in HIV unexposed individuals: A study from Mumbai.
    Chaudhari DV; Kerkar SC; Chavan V; Mehta PR; Mania-Pramanik J
    Indian J Dermatol Venereol Leprol; 2015; 81(5):548. PubMed ID: 26087087
    [No Abstract]   [Full Text] [Related]  

  • 15. DNA vaccines expressing soluble CD4-envelope proteins fused to C3d elicit cross-reactive neutralizing antibodies to HIV-1.
    Bower JF; Green TD; Ross TM
    Virology; 2004 Oct; 328(2):292-300. PubMed ID: 15464849
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adaptation to promiscuous usage of chemokine receptors is not a prerequisite for human immunodeficiency virus type 1 disease progression.
    de Roda Husman AM; van Rij RP; Blaak H; Broersen S; Schuitemaker H
    J Infect Dis; 1999 Oct; 180(4):1106-15. PubMed ID: 10479137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and immunogenicity of an HIV subtype B and E prime-boost vaccine combination in HIV-negative Thai adults.
    Nitayaphan S; Pitisuttithum P; Karnasuta C; Eamsila C; de Souza M; Morgan P; Polonis V; Benenson M; VanCott T; Ratto-Kim S; Kim J; Thapinta D; Garner R; Bussaratid V; Singharaj P; el-Habib R; Gurunathan S; Heyward W; Birx D; McNeil J; Brown AE;
    J Infect Dis; 2004 Aug; 190(4):702-6. PubMed ID: 15272397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of HIV-1 specific T lymphocyte responses in highly exposed persistently seronegative Chinese.
    Liu HW; Hong KX; Ma J; Yuan L; Liu S; Chen JP; Zhang YZ; Ruan YH; Xu JQ; Shao YM
    Chin Med J (Engl); 2006 Oct; 119(19):1616-21. PubMed ID: 17042974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and immunogenicity of combinations of recombinant subtype E and B human immunodeficiency virus type 1 envelope glycoprotein 120 vaccines in healthy Thai adults.
    Pitisuttithum P; Nitayaphan S; Thongcharoen P; Khamboonruang C; Kim J; de Souza M; Chuenchitra T; Garner RP; Thapinta D; Polonis V; Ratto-Kim S; Chanbancherd P; Chiu J; Birx DL; Duliege AM; McNeil JG; Brown AE;
    J Infect Dis; 2003 Jul; 188(2):219-27. PubMed ID: 12854076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of high-risk HIV-1 seronegative hemophiliacs.
    Salkowitz JR; Purvis SF; Meyerson H; Zimmerman P; O'Brien TR; Aledort L; Eyster ME; Hilgartner M; Kessler C; Konkle BA; White GC; Goedert JJ; Lederman MM
    Clin Immunol; 2001 Feb; 98(2):200-11. PubMed ID: 11161976
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.